(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 July 2011 (14.07.2011)

PCT

(10) International Publication Number
WO 2011/085158 A3

(51) International Patent Classification:
A61K 9/08 (2006.01) *A61K 9/00* (2006.01)
A61K 31/485 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/US2011/020457

(22) International Filing Date:
7 January 2011 (07.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/293,227 8 January 2010 (08.01.2010) US
12/986,223 7 January 2011 (07.01.2011) US

(71) Applicant *(for all designated States except US)*: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US).

(72) Inventors; and
(71) Applicants : **DIX, Daniel, B.** [US/US]; 55 Memory Trail, Lagrangeville, NY 12540 (US). **GRAHAM, Kenneth, S.** [US/US]; 218 Robbout Road, Pleasant Valley, NY 12569 (US). **KAMEN, Douglas, E.** [US/US]; 21 Lyndsey Lane, Poughquag, NY 12570 (US). **WALSH, Scott, M.** [US/US]; 302 Watch Hill Dr, Tarrytown, NY 10591 (US).

(74) Agent: **ZAHNER, Joseph, E.**; Senior Patent Agent, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
22 March 2012

(54) Title: STABILIZED FORMULATIONS CONTAINING ANTI-INTERLEUKIN-6 RECEPTOR (IL-6R) ANTIBODIES




Figure 1

(57) Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

WO 2011/085158 A3